<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01331655</url>
  </required_header>
  <id_info>
    <org_study_id>14700</org_study_id>
    <nct_id>NCT01331655</nct_id>
  </id_info>
  <brief_title>Clinical Study of a Conventional and Flexible Extended Oral Contraceptive of EE/DRSP With or Without Metafolin in Latin America</brief_title>
  <official_title>A Multicenter, Open-label, 3-arm, Active-controlled, Parallel-group, 1-year Study to Investigate the Efficacy and Safety of a Flexible Regimen of the Combined Oral Contraceptive, With and Without 0.451 mg Levomefolate Calcium (BAY98-7071 and BAY86-5300, Respectively) Versus the Standard 24 + 4 Regimen With Levomefolate (BAY98-7071 + BAY86-7660) and to Assess Compliance With a Device (CADDY) in Healthy Women Who Desire Contraception</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this three-arm study is to evaluate the effect of a flexible extended
      regimen of an EE+DRSP containing OC on bleeding pattern and to investigate the compliance
      with daily pill intake when the investigational product is provided in a blister package or a
      compliance aiding dispenser with a pill reminder function. The third treatment arm will be a
      reference comparator arm of a standard 24+4 regimen of the identical hormone combination.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of bleeding days</measure>
    <time_frame>Approximately 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in the number of missed tablets between Arms A and B</measure>
    <time_frame>Approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding pattern and cycle control parameters</measure>
    <time_frame>Approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cycles per subject</measure>
    <time_frame>Approximately 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EE20/DRSP (BAY86-5300)</intervention_name>
    <description>Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP (1 tablet/day); up to 120-day treatment period followed by a 4-day tablet-free interval</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EE20/DRSP/L-5-MTHF (BAY98-7071)</intervention_name>
    <description>Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium (1 tablet/day) up to 120-day treatment period followed by a 4-day tablet-free interval</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660)</intervention_name>
    <description>Day 1-24: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium per tablet (1 tablet/day) Day 25-28: tablets with 0.451 mg levomefolate calcium (1 tablet/day)</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female volunteers between 18 and 35 years of age (smokers up to 30 years,
             inclusive) who request contraceptive protection

        Exclusion Criteria:

          -  Pregnancy or lactation (less than 3 months since delivery, abortion, or lactation
             before start of treatment)

          -  Body mass index (BMI) &gt;/= 30.0 kg/m2

          -  Presence or a history of venous or arterial thrombotic/thromboembolic events

          -  Repeated measurements of systolic blood pressure &gt; 140 mmHg and/or diastolic blood
             pressure &gt; 90 mmHg

          -  Presence or history of liver tumors (benign or malignant), severe hepatic disease,
             jaundice and/or pruritus related to cholestasis, cholestatic jaundice associated with
             pregnancy or previous combined oral contraceptive (COC) use

          -  Uncontrolled diabetes mellitus and/or diabetes mellitus with vascular involvement

          -  Severe dyslipoproteinemia

          -  Malignant or premalignant disease

          -  Uncontrolled thyroid disorder

          -  Chronic inflammatory bowel disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <removed_countries>
    <country>Brazil</country>
    <country>Mexico</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <last_update_submitted>July 14, 2014</last_update_submitted>
  <last_update_submitted_qc>July 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Tetrahydrofolates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

